Akums Drugs and Pharmaceuticals Limited — Updates, 09-11-2024: Press Release

Akums Drugs and Pharmaceuticals reported a Q2 profit after tax (PAT) of ₹667 million, up 16% sequentially. Total income increased by 2% to ₹10,466 million, while adjusted EBITDA rose 3% to ₹1,347 million. The company noted a decline in year-over-year performance due to lower API prices and fluctuating demand but remains optimistic about future growth. With a solid cash surplus of ₹3,406 million, Akums plans to invest in R&D and expand its capabilities in the CDMO sector.